State Street Corp Purchases 5,501,032 Shares of Pfizer Inc. $PFE

Key Points

• State Street increased its Pfizer position by 1.8% in the second quarter, purchasing 5.5 million additional shares and bringing its total holdings to 307.1 million shares, worth approximately $7.4 billion.
• Several major institutions also added to Pfizer holdings, with institutional investors collectively owning 68.36% of the company. BlackRock remains the largest listed institutional holder with about 529.7 million shares.
• Pfizer’s stock traded near $27.83, while analysts maintained a consensus “Hold” rating and a $28.39 price target. The company offers a 6.2% dividend yield, but patent expirations, declining COVID-19 revenue and execution risks continue to weigh on its outlook.

State Street Corp raised its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 1.8% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 307,090,897 shares of the biopharmaceutical company's stock after buying an additional 5,501,032 shares during the quarter. State Street Corp owned about 5.39% of Pfizer worth $7,394,749,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. BlackRock Inc. grew its holdings in Pfizer by 6.3% in the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company's stock worth $12,754,464,000 after purchasing an additional 31,412,883 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Pfizer by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company's stock worth $3,235,642,000 after purchasing an additional 1,184,728 shares in the last quarter. Norges Bank acquired a new stake in shares of Pfizer in the 4th quarter worth $1,830,986,000. Bank of New York Mellon Corp grew its stake in Pfizer by 7.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 57,879,546 shares of the biopharmaceutical company's stock worth $1,393,739,000 after buying an additional 3,999,646 shares during the last quarter. Finally, Fisher Asset Management LLC increased its position in Pfizer by 5.4% during the 4th quarter. Fisher Asset Management LLC now owns 51,952,106 shares of the biopharmaceutical company's stock valued at $1,293,607,000 after buying an additional 2,664,052 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Management’s message that tariffs, drug-pricing pressures, declining COVID-19 revenue and upcoming patent expirations are becoming more manageable is supporting the recovery narrative. Cost-cutting efforts and a larger contribution from newer therapies could help offset declining legacy-product sales. Pfizer’s agreement to share some additional overseas pricing revenue with the U.S. Department of Health and Human Services may also reduce regulatory uncertainty. How Investors Are Reacting To Pfizer Easing Policy Pressures And New HHS Revenue-Sharing Deal
• Positive Sentiment: Pfizer completed a key Phase 1 study for PF-07799544, advancing the experimental drug into the next stage of development. Although early-stage data do not establish commercial success, continued pipeline progress could improve confidence in Pfizer’s post-patent-expiry growth prospects. Pfizer Advances PF-07799544 With Completion of Key Phase 1 Study
• Positive Sentiment: Several investment commentaries argue that Pfizer’s valuation and dividend yield already reflect substantial pessimism, leaving room for a potential re-rating if earnings stabilize after major loss-of-exclusivity events. The roughly 6% yield remains attractive to income-oriented investors. Pfizer: A Conservative Valuation Leaves Room For A Post-LOE Re-Rating
• Neutral Sentiment: CEO Albert Bourla reportedly plans to attend the White House state dinner for Chinese President Xi Jinping. The appearance could support visibility around U.S.-China pharmaceutical relations, but it has no immediate, clearly measurable earnings impact. Pfizer CEO Bourla plans to attend White House state dinner for China's Xi
• Negative Sentiment: More cautious analysis says investors may not pay for Pfizer’s 2029 earnings potential until the company demonstrates durable growth, while dividend increases appear limited. Patent expirations, weak COVID-related sales and execution risk continue to constrain the stock’s upside. Pfizer: The Market Won't Pay For 2029 Until It Can

Pfizer Price Performance

Shares of NYSE PFE traded up $0.09 during midday trading on Tuesday, hitting $27.83. The stock had a trading volume of 11,582,337 shares, compared to its average volume of 41,026,941. The stock has a 50 day simple moving average of $26.77 and a 200-day simple moving average of $26.38. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $158.61 billion, a PE ratio of 36.63, a P/E/G ratio of 1.86 and a beta of 0.34. Pfizer Inc. has a 1 year low of $23.58 and a 1 year high of $29.21.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts' consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business's revenue was up 2.6% on a year-over-year basis. During the same period last year, the company posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 1st. Investors of record on Friday, July 24th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.2%. The ex-dividend date was Friday, July 24th. Pfizer's payout ratio is currently 226.32%.

Wall Street Analysts Forecast Growth

PFE has been the subject of several recent analyst reports. Cantor Fitzgerald reissued a "neutral" rating and issued a $27.00 price target on shares of Pfizer in a report on Monday, July 6th. HSBC upped their target price on Pfizer from $28.00 to $30.00 and gave the company a "hold" rating in a research report on Thursday, September 10th. Bank of America lowered their price target on Pfizer from $27.00 to $26.00 and set a "neutral" rating for the company in a research report on Friday, July 10th. JPMorgan Chase & Co. dropped their price target on Pfizer from $30.00 to $28.00 and set a "neutral" rating on the stock in a research note on Wednesday, July 8th. Finally, Guggenheim reduced their price objective on Pfizer from $35.00 to $31.00 and set a "buy" rating for the company in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $28.39.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer's products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.